Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Leiomyosarcoma × niraparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 37 Prostatic Neoplasms 11 Breast Neoplasms 10 Fallopian Tube Neoplasms 9 Pancreatic Neoplasms 7 Glioblastoma 6 Neoplasm Metastasis 5 Endometrial Neoplasms 5 Neoplasms 4 Lung Neoplasms 4 Glioma 4 Triple Negative Breast Neoplasms 3 Small Cell Lung Carcinoma 3 Mesothelioma 3 Cholangiocarcinoma 3 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma 2 Recurrence 2 Mesothelioma, Malignant 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Ovarian Epithelial 2 Brain Neoplasms 2 Biliary Tract Neoplasms 2 Uveal Melanoma 1 Uterine Neoplasms 1 Urothelial Cancer 1 Unilateral Breast Neoplasms 1

Interventions

Gemcitabine 14 Docetaxel 8 Doxorubicin 7 Radiotherapy 6 Trabectedin 5 pazopanib 4 Sunitinib 3 Nivolumab 3 Dacarbazine 3 liposomal doxorubicin 2 eribulin 2 avelumab 2 Specimen Handling 2 Radiation Dose Hypofractionation 2 Letrozole 2 Ifosfamide 2 Bevacizumab 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 tremelimumab 1 temsirolimus 1 sotigalimab 1 selinexor 1 sargramostim 1 ribociclib 1 regorafenib 1 pembrolizumab 1 pegfilgrastim 1 niraparib 1 lenvatinib 1 lentiviral minigene vaccine of COVID-19 coronavirus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05174455 2023-09-18

Niraparib for the Treatment of Leiomyosarcoma

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡